20/20 Biolabs, Inc.
No SEC Form 4 filings for $AIDX in the last 30 days.
See all $AIDX insider activity →20/20 Biolabs, Inc. (AIDX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. As previously disclosed, on August 18, 2026, 20/20 Biolabs, Inc. (the “Company”) convened its annual meeting of stockholders of the Company (the “Annual Meeting”). At the Annual Meeting, the Company did not receive a
20/20 Biolabs, Inc. (AIDX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 18, 2026, 20/20 Biolabs, Inc. (the “Company”) held an annual meeting of stockholders of the Company (the “Annual Meeting”) via live webcast. Holders of shares of the Company’s common stock at the close of bu
20/20 BioLabs (AIDX) reported Q2 2026 revenue up 36.5% to $0.7M. OneTest revenue rose 47.1% to $0.7M and was 95.3% of total revenue. Gross margin increased to 41.7% from 30.5%. Operating expenses rose to $1.5M; net loss widened to $1.5M ($0.26/share). Cash was $4.5M at June 30, 2026.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AIDX (20/20 Biolabs, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent AIDX coverage spans financial news, corporate actions and earnings.
The amendment could dilute existing shareholders but provides capacity for future equity raises.
The filing confirms board elections and approval of the equity incentive plan, but no immediate financial impact.
The print shows accelerating OneTest revenue concentration and improving unit economics, but losses widened and cash remains modest.
The 8-K provides fresh operating and balance-sheet datapoints plus financing overhang updates (convertible notes eliminated, 120-day standstill).
The standstill can reduce near-term dilution/overhang from preferred conversions, but it also preserves Investor’s conversion rights after the period or upon breach.
AlphAI scores every news story that mentions AIDX with an AI model for sentiment and relevance, and aggregates insider trades from 20/20 Biolabs, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
20/20 Biolabs, Inc. (AIDX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. As previously disclosed, on August 18, 2026, 20/20 Biolabs, Inc. (the “Company”) convened its annual meeting of stockholders of the Company (the “Annual Meeting”). At the Annual Meeting, the Company did not receive a
1 min read20/20 Biolabs, Inc. (AIDX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 18, 2026, 20/20 Biolabs, Inc. (the “Company”) held an annual meeting of stockholders of the Company (the “Annual Meeting”) via live webcast. Holders of shares of the Company’s common stock at the close of bu
1 min read20/20 BioLabs (AIDX) reported Q2 2026 revenue up 36.5% to $0.7M. OneTest revenue rose 47.1% to $0.7M and was 95.3% of total revenue. Gross margin increased to 41.7% from 30.5%. Operating expenses rose to $1.5M; net loss widened to $1.5M ($0.26/share). Cash was $4.5M at June 30, 2026.
5 min read20/20 Biolabs, Inc. (AIDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level Total Revenue Increased 37% to $0.7 Million and Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding
6 min read20/20 Biolabs, Inc. (AIDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ea029890701ex10-1.htm STANDSTILL AGREEMENT, DATED JULY 16, 2026, BETWEEN STREETERVILLE CAPITAL, LLC AND 20/20 BIOLABS, INC Exhibit 10.1 STANDSTILL AGREEMENT This Standstill Agreement (this “ Agreement ”) is entered into as of July 16, 2026 (the “ Effective Date ”) by an
3 min read20/20 BioLabs (Nasdaq: AIDX) discussed in an investor webinar its OneTest for Cancer strategy for potential Medicare coverage of FDA-authorized MCED blood tests starting in 2028. The company said OneTest uses protein biomarkers and serial tracking, not ctDNA-only. It expects Q2 MCED revenue to be its highest, at least 30% above Q2 2025, based on preliminary figures.
5 min read20/20 BioLabs (AIDX) reported a 17% increase in 2025 revenue to $2.0 million, with significant improvement in gross margin to 29.6% and a 33% reduction in net loss to $3.7 million. This financial improvement was driven by a shift to higher-margin revenue streams and decreased operating expenses. The company also secured a $5.0 million tranche under a potential $40 million preferred purchase agreement and highlighted future growth drivers like a state-funded firefighter cancer screening program and the launch of OneTest for Longevity.
4 min read20/20 Biolabs reported fiscal-year revenue of $2.045 million, a 16.7% increase, driven by higher OneTest and CLIAx sales and a shift to a premium test mix. The company recorded a net loss of $(3.739) million, an improvement of 32.7% versus the prior year, with gross profit increasing to $0.605 million. Operational developments include the launch of OneTest for Longevity and expansion into multi-cancer screenings for veterans.
2 min readThis article lists 12 healthcare stocks that experienced significant movement during Monday's intraday trading session. It highlights several gainers, including Arcellx (NASDAQ: ACLX) and Vanda Pharmaceuticals (NASDAQ: VNDA), and several decliners such as Gossamer Bio (NASDAQ: GOSS) and 20/20 Biolabs (NASDAQ: AIDX), along with their respective percentage changes and market caps.
4 min read
